Baxter International Inc. (BAX)
Baxter International Inc. is a global healthcare company specializing in medical products and services, including dialysis, intravenous solutions, and biopharmaceuticals. Founded in 1931, the company focuses on supporting patient care through innovative therapies and medical devices across hospitals, clinics, and homes worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 1, 2025 | $0.17 | 2025-08-29 | 2025-08-29 |
| July 1, 2025 | $0.17 | 2025-05-30 | 2025-05-30 |
| April 1, 2025 | $0.17 | 2025-02-28 | 2025-02-28 |
| January 2, 2025 | $0.17 | 2024-11-29 | 2024-11-29 |
| October 1, 2024 | $0.29 | 2024-08-30 | 2024-08-30 |
Dividends Summary
- Baxter International Inc. has issued 80 dividend payments over the past 21 years
- The most recent dividend was paid 21 days ago, on October 1, 2025
- The highest dividend payed out to investors during this period was $0.58 per share
- The average dividend paid during this period was $0.29 per share.
Company News
A shareholder lawsuit has been filed against Baxter International Inc. alleging misrepresentations about the safety of its Novum IQ Large Volume Pump, which potentially put patients at risk of severe injury and death.
The U.S. Commerce Department launched a national security review of medical imports to assess reliance on foreign suppliers for critical health products, examining medical devices, PPE, and consumables under Section 232 of the Trade Expansion Act.
Baxter International Inc. reported better-than-expected Q2 2024 earnings, with adjusted EPS of 68 cents beating the consensus estimate. Revenue also topped expectations, driven by growth across the company's business segments. The company provided positive guidance for Q3 and full-year 2024.
Morgan Stanley downgraded Baxter International's stock from Equalweight to Underweight, citing concerns over the company's ability to meet its margin goals, particularly after its acquisition of Hillrom. The firm lowered its price target for Baxter to $30 from $39, reflecting a more conservative outlook on the company's mid-term earnings.
